Dovato vs Biktarvy vs Triumeq: How the Three Single-Tablet HIV Regimens Compare

Biktarvy, Dovato and Triumeq are three of the most prescribed HIV medicines in the world. All three are a single tablet taken once a day, all three are built around an integrase inhibitor, and all three are recommended options for starting treatment in current guidelines⁷⁸.

So people reasonably ask: which one is better? There is no single winner. Each suits some people more than others, and a few simple facts about your health usually point clearly to one or two of them. This guide walks through those facts. It is meant to help you have a better conversation with your HIV team, not to replace it.

What is inside each tablet

Sources: US prescribing information and European product information for each medicine¹²³⁴⁵⁶, and the NIH list of approved HIV medicines⁹.

Three drugs or two: who Dovato is for

Dovato is the odd one out. It contains only two HIV medicines, where most regimens contain three. For many people that is plenty: in the trials that led to its approval, it worked as well as a three-drug regimen in adults starting treatment.

Those trials, though, only included people without hepatitis B, without known drug resistance, and with a viral load of up to 500,000 copies/mL before treatment². That shapes who it suits today:

• Not if you have hepatitis B. The lamivudine in Dovato is not enough to control hepatitis B on its own, and hepatitis B can become resistant to it. The US label carries a boxed warning about this².
• Not if your virus is already resistant to dolutegravir or lamivudine.
• Very high viral load at the start. Doctors have traditionally been cautious about Dovato when the viral load is very high or before resistance and hepatitis B results are back. A newer study, VOGUE, included exactly these people and found Dovato worked as well as Biktarvy (see below), so ask whether your clinic’s guidance has changed.
• Not if your kidneys are working well below normal. Dovato is not recommended when kidney function (creatinine clearance) is below 30 mL/min, because the fixed tablet cannot be adjusted².

Dovato is also approved for people who are already undetectable on another regimen and want to switch, as long as they have no history of treatment failure or resistance².

What the head-to-head trials found

For years there was no direct comparison of Dovato and Biktarvy. Now there are two, and they are the studies AI tools and doctors quote most often.

• PASO-DOBLE (switching). 553 adults in Spain who were already undetectable on older regimens were switched either to Dovato or to Biktarvy. After 48 weeks, Dovato kept HIV under control just as well as Biktarvy. Most side effects in both groups were mild and judged unrelated to the medicines, and slightly fewer severe ones were reported with Dovato¹¹. By 96 weeks, both groups had put on some weight, but the Dovato group gained significantly less, and more people on Biktarvy gained over 5% of their starting weight¹². People who had taken dolutegravir or bictegravir before were not included, so this tells us about switching to each pill, not about moving from Biktarvy to Dovato.
• VOGUE (starting treatment). 509 adults starting HIV treatment for the first time, including people with very high viral loads and low CD4 counts, were given either Dovato or Biktarvy before their resistance results were back. At 48 weeks Dovato worked as well as Biktarvy, the virus became undetectable in about four weeks in both groups, and no drug resistance developed in either¹³. These results were presented at the AIDS 2026 conference in July 2026 and have not yet been published in a journal.

Two things to keep in mind. PASO-DOBLE was partly funded by ViiV Healthcare, which makes Dovato, and the VOGUE results so far come from a ViiV announcement. And US guidelines say HIV medicines should not be chosen or switched just to avoid weight gain, because the evidence suggests this does not work¹⁴. The weight difference is worth knowing about, but it is one factor among several.

Triumeq and the HLA-B*5701 test

Triumeq contains abacavir. A small proportion of people carry a gene variant called HLA-B*5701, and in them abacavir can trigger a serious allergic-type reaction, with fever, rash, stomach upset, tiredness or breathing symptoms. Triumeq must not be used in anyone who tests positive for HLA-B*5701, so the gene test is done before it is prescribed³.

Even with a negative test, anyone who has a suspected reaction stops Triumeq and is never given abacavir again, because a second reaction can be much worse³. Your pharmacist will give you a warning card to keep with you.

There is a second question mark over abacavir. Some observational studies have linked it to a higher risk of heart attack, while combined analyses of randomised trials have not found that extra risk. The US label covers both findings and advises care in people already at high risk of heart disease³. If you have heart disease or several risk factors, this is worth raising.

Hepatitis B: the biggest dividing line

Around the world, many people with HIV also have hepatitis B, and that one fact changes the choice more than any other.

• Biktarvy contains emtricitabine and tenofovir alafenamide, both of which are active against hepatitis B. It treats both infections at once¹.
• Dovato and Triumeq contain lamivudine but no tenofovir, which is not enough for hepatitis B. People with both infections need a regimen that includes tenofovir²³.

One warning applies to all three. If you have hepatitis B, stopping any of these medicines suddenly can cause a serious flare of liver inflammation¹². Never stop without your doctor’s plan. Our hepatitis B treatment guide explains why.

Side effects: more alike than different

Most people take any of the three with few or no side effects after the first few weeks. The European leaflets list similar common effects for all three: headache, diarrhoea, feeling sick, tiredness, abnormal dreams and weight gain⁴⁵⁶.

A few differences people notice:

• Sleep. Difficulty sleeping is listed as very common with Triumeq and common with Dovato, both of which contain dolutegravir⁵⁶. Taking the tablet in the morning helps some people.
• Weight. Weight gain is listed as a common side effect for all three. Our guide to HIV medicines and weight gain looks at what the research shows.
• Kidney blood tests. Bictegravir and dolutegravir both raise a blood test called creatinine slightly in the first few weeks. The labels explain that this comes from how the kidneys handle creatinine, not from damage to the kidneys¹². Your clinic knows to expect it.

Interactions: what to tell every prescriber

All three share some interaction rules, because they are all integrase inhibitors¹²³:

• Antacids and supplements. Antacids or laxatives containing aluminium or magnesium stop the tablet being absorbed properly. Take the HIV tablet at least 2 hours before, or 6 hours after, them. Calcium or iron supplements can be taken at the same time only if you take them together with food.
• Metformin. All three raise the level of metformin, the diabetes medicine, so your doctor may check your dose.
• The TB medicine rifampicin. It must not be taken with Biktarvy. With Dovato or Triumeq, an extra dolutegravir tablet is added 12 hours later to make up for it¹²³.
• St John’s wort and some epilepsy medicines lower the levels of these drugs.

The free Liverpool HIV interactions checker¹⁰ is what many pharmacists use, and you can use it too.

Pregnancy

The US Biktarvy label now includes a dose for people who become pregnant while already undetectable on a stable regimen. Drug levels run a little lower in pregnancy, so the label asks for closer viral load checks¹. If you are pregnant or planning to be, whichever pill you take, raise it with your HIV team early so they can plan your monitoring.

Switching between them

People switch for all kinds of reasons: side effects, a new diagnosis like hepatitis B, wanting fewer drugs, or a change in what their insurance or health service covers. Common moves include:

• Triumeq to Dovato, to drop abacavir while keeping dolutegravir.
• Biktarvy to Dovato, to take two drugs instead of three, but only if there is no hepatitis B.
• Dovato or Triumeq to Biktarvy, often after a hepatitis B diagnosis.

A switch is usually made while you are undetectable, and your clinic will check your viral load a few weeks afterwards to make sure the new regimen is holding. Do not switch on your own, even between pills that look similar.

Generic versions and cost

All three are expensive as brands. Licensed generic versions are made in India and used widely in many countries. For example, Taffic contains the same three ingredients as Biktarvy. Our pages on generic Biktarvy, generic Dovato and generic Triumeq cover what is available and what it costs. Whether you can import a generic for personal use depends on your country’s rules: see our guides for the UK, the USA and Australia.

So which one suits whom?

Outside those situations, all three are good options and the choice often comes down to side effects, other medicines and cost. For a wider view of HIV medicines, see our list of HIV medication names and Biktarvy explained.

Frequently asked questions

Is Biktarvy better than Triumeq?

Not overall. Both are recommended starting options. Biktarvy also treats hepatitis B and does not need the HLA-B*5701 test, while Triumeq suits people who prefer a dolutegravir-based pill and test negative for HLA-B*5701. The right choice depends on your health and other medicines.

Can Dovato be used as PrEP?

No. Dovato is approved for treating HIV, not preventing it. PrEP uses different medicines, such as emtricitabine with tenofovir. See our PrEP guide.

Why would someone switch to Dovato?

Usually to take two HIV drugs instead of three, or to stop abacavir or tenofovir, while keeping an undetectable viral load. It is only suitable for people without hepatitis B and without resistance to its ingredients.

Which of the three has the fewest side effects?

There is no clear winner. Their common side effects are similar and usually mild. Sleep problems are more often reported with the dolutegravir-based pills, Dovato and Triumeq. Everyone responds differently, so tell your team if a side effect bothers you.

What can replace Biktarvy?

Several one-pill regimens can, including Dovato and Triumeq, and for people who are already undetectable there are newer switch options such as Idvynso and Bixlenvo. Long-acting injections are another route for some people. The right replacement depends on hepatitis B, past resistance, kidney function and your other medicines, so it is chosen with your HIV team.

Can Dovato cause liver damage?

Liver problems have been reported with dolutegravir-based treatment, and people who also have hepatitis B or C are at higher risk. That is why liver blood tests are part of routine monitoring. Tell your clinic straight away about yellowing skin or eyes, dark urine, or pain under the right ribs.

Can I take these with antacids or vitamins?

Yes, with care. Take the HIV tablet at least 2 hours before or 6 hours after antacids containing aluminium or magnesium. Calcium or iron supplements can be taken at the same time if you take everything with food.

Sources & references

1. US National Library of Medicine, DailyMed. Biktarvy prescribing information.
2. US National Library of Medicine, DailyMed. Dovato prescribing information.
3. US National Library of Medicine, DailyMed. Triumeq prescribing information.
4. European Medicines Agency. Biktarvy: product information.
5. European Medicines Agency. Dovato: product information.
6. European Medicines Agency. Triumeq: product information.
7. National Institutes of Health (HIVinfo). Starting an HIV Treatment Regimen.
8. British HIV Association (BHIVA). Clinical guidelines.
9. National Institutes of Health (HIVinfo). FDA-Approved HIV Medicines. Last reviewed 4 September 2026.
10. University of Liverpool. HIV Drug Interactions checker.
11. Ryan P, Blanco JL, Masia M, et al. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results. The Lancet HIV. 2025;12(7):e473-e484.
12. ViiV Healthcare (manufacturer). PASO DOBLE trial data, including 96-week weight results.
13. ViiV Healthcare press release, 27 July 2026. VOGUE week-48 data presented at AIDS 2026.
14. US Department of Health and Human Services, Clinicalinfo. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents: Weight Gain in People With Treated HIV. Updated 25 September 2025.

Related reading

• Biktarvy explained
• Dolutegravir-based treatment: your first 90 days
• Chronic hepatitis B treatment guide
• All HIV and PrEP medicines

This content is for informational purposes only and is not medical advice. The right regimen depends on your test results, other conditions and other medicines, and is chosen with your HIV team. Never switch or stop HIV medicine on your own. Used as prescribed by a licensed medical professional.